Circular RNA vaccines against monkeypox virus provide potent protection against vaccinia virus infection in mice.
Mol Ther
; 32(6): 1779-1789, 2024 Jun 05.
Article
em En
| MEDLINE
| ID: mdl-38659224
ABSTRACT
Since the outbreak of monkeypox (mpox) in 2022, widespread concern has been placed on imposing an urgent demand for specific vaccines that offer safer and more effective protection. Using an efficient and scalable circular RNA (circRNA) platform, we constructed four circRNA vaccines that could induce robust neutralizing antibodies as well as T cell responses by expressing different surface proteins of mpox virus (MPXV), resulting in potent protection against vaccinia virus (VACV) in mice. Strikingly, the combination of the four circular RNA vaccines demonstrated the best protection against VACV challenge among all the tested vaccines. Our study provides a favorable approach for developing MPXV-specific vaccines by using a circular mRNA platform and opens up novel avenues for future vaccine research.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Vaccinia virus
/
Monkeypox virus
/
Anticorpos Neutralizantes
/
RNA Circular
Limite:
Animals
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article